SUI GROUP HOLDINGS LIMITED financials

SUIG CIK 0001425355

Source: EDGAR filings · Built 2026-06-19T01:36:32Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Working Capital 17.59M 19.76M
Net Debt -6.03M -366.74K -1.07M -1.86M -5.41M
Operating Margin -6772.57% 48.26%
Net Margin -6825.01% 35.37%
Return on Equity (ROE) -156.76% 5.91%
Return on Assets (ROA) -139.77% 5.70%
Current Ratio 2.38× 28.62×
Debt-to-Equity 0.00× 0.00× 0.00× 0.01× 0.00×
Effective Tax Rate -0.28% 26.70%
Cash Conversion Ratio 0.03× 4.84×
Accruals Ratio -1.35× -0.22×
SBC % of Revenue 113.68% 0.00%

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Revenues 3.90M 3.30M
Operating Expenses 267.94M 1.71M 3.72M 3.40M 1.35M 735.79K
Operating Income (Loss) -264.04M 1.59M
Income Tax Expense (Benefit) 743.44K 425.45K -454.55K 9.65K 1.05M 288.40K
Net Income (Loss) Attributable to Parent -266.08M
Earnings Per Share, Basic $-6.59 $0.18 $-0.18 $0.02 $0.59 $0.20
Weighted Average Number of Shares Outstanding, Basic 40.21M 6.39M 6.25M 5.33M 4.80M 10.87M
Earnings Per Share, Diluted $-6.59 $0.18 $0.26 $0.20
Weighted Average Number of Shares Outstanding, Diluted 40.21M 6.49M 6.37M 5.33M 4.80M 4.83M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Cash and Cash Equivalents, at Carrying Value 6.03M 376.02K 1.09M 1.94M 5.44M
Assets, Current 30.31M 20.47M
Assets 190.36M 20.47M 19.11M 18.73M 16.70M 12.51M
Liabilities, Current 12.72M 715.45K
Liabilities 20.62M 715.45K 516.43K 863.23K 3.28M 870.00K
Stockholders' Equity Attributable to Parent 169.74M 19.76M 18.59M 17.87M 13.41M 11.64M
Common Stock, Shares, Outstanding 76.80M 6.39M 6.39M 6.19M 4.80M 4.79M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Net Cash Provided by (Used in) Operating Activities -8.24M 5.65M -1.14M -4.89M -1.89M -2.46M
Net Cash Provided by (Used in) Investing Activities -195.36M 0
Payments for Repurchase of Common Stock 18.93M 0 162.92K
Net Cash Provided by (Used in) Financing Activities 219.50M 0 424.00K 4.04M -1.62M -162.92K

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (SUIG CIK 0001425355), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

NAMSW

NewAmsterdam Pharma Company N.V.

VLYPO

VALLEY NATIONAL BANCORP

DRTS

Alpha Tau Medical Ltd.